SunEdison Inc. (NYSE: SUNE) showed an increase of 3.9% in short interest, to 93.88 million shares. About 30.1% of the company’s float is now short and days to cover rose from two to three. In the latest two-week short interest reporting period, the share price added more than 9%, after dropping more than 30% in the prior two weeks. The stock closed at $9.07 Thursday night, down about 2.6% for the day, in a 52-week range of $8.10 to $33.45.
WHEN WILL THE BEARS BE SUCKED AS BEEF?
I bought 1200 at $8.30 this morning and got roasted like a ?? There are crooks on wall street. I just don't see any rationale for this terrible fall. The market is down 2-3% and this pig sank 19%!! Ooops!
You are smart.. I should do the same as this is a poisonous devil in the making. Look at the volume....terrible!
Today's investors are more interested in short term gains that fundamental investments. TTPH was dumb by investors with smart brain as they scrutinized TTPH pipeline and observed a "one-drug-dependency" strategy. This company has 55 employees. They were luck to mine into precious antibiotic, yet their phase III failed. Go to their websites and you will see that all further development with any prospects were surrogates of TP-271, hence its failure should actually drive the stock to $2. There is nothing else left. It is an empty basket, because it will be foolish to continue to spend money on other antibiotic compounds with similar profiles with TTPH.
Why is the stock surging? FRAUD with the intention of dumping without notice. No smart pharma will perform due diligence on this company and pay more than $20 million (too generous).
Note: This is a generic drug development company primarily focused on tetracycline class of antibiotics. There is nothing novel or breakthrough in what TTPH is doing, hence I caution investors.
Sentiment: Strong Sell
Yes, the phase II result is impressive. But Investors need to be cautious not to over invest. There is still the risk that Phase III may not work as designed. Drug development business is risky at best!
Stop kidding yourself. I am a clinical statistician. The primary end point did not show statistical significance. The rest is data massaging. If they have money, they can reconstruct the study to adaptive design, that is if the FDA will let them go that route.
See company disclaim statement below and rethink your stand:
Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the status, timing, costs, results and interpretation of the company’s clinical trials, including the Company’s interpretation of the efficacy, safety and tolerability results from the Phase 2b study of TRV130 as compared to placebo and morphine and whether TRV130 ultimately will provide a better treatment option than existing opioids for patients with moderate to severe acute pain; the uncertainties inherent in conducting clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or results of completed clinical trials will be indicative of the results of future trials, including with respect to whether the results of this Phase 2b study of TRV130 as well as prior clinical studies of this molecule will be consistent with the results obtained in any future Phase 3 studies; expectations for regulatory approvals; availability of funding sufficient for the company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; other matters that could affect the viability or commercial potential of the company’s therapeutic candidates; the inherent uncertainties associated with intellectual property; and other factors discussed in the Risk Factors set forth in the company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings the company makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent the company’s views only as of the date hereof. The company anticipates that subsequent events and developments may cause the company’s views to change. However, while the company may elect to update these forward-looking statements at some point
AGREED WITH YOU.
Design is "adaptive" meaning cheating method.
Study center was on 1....ridiculous
And worse, as the does increases so do safety events
Some of the analysts need to go to jail!
The run is more speculative than real here. No drug approval yet and they still have to conduct Phase III study which may run for another 9 months. Also, note that this company went public a few months ago. Any trigger could pull the stock back to $7 which is above fair value. Yes, the result of phase IIb is impressive, but no drug yet. Do not say I warn you. Good luck